DGAP-Adhoc: Biofrontera AG: Biofrontera Reports Positive Phase III Results with Ameluz(R) for photodynamic therapy of actinic keratoses on the extremities and trunk/neck

2019. március 20., szerda, 15:50





DGAP-Ad-hoc: Biofrontera AG / Key word(s): Study results


Biofrontera AG: Biofrontera Reports Positive Phase III Results with Ameluz(R) for photodynamic therapy of actinic keratoses on the extremities and trunk/neck


20-March-2019 / 15:50 CET/CEST


Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.


The issuer is solely responsible for the content of this announcement.




Ad-hoc Release pursuant to Art. 17 MAR

Biofrontera Reports Positive Phase III Results with Ameluz(R) for photodynamic therapy of actinic keratoses on the extremities and trunk/neck



Leverkusen, Germany, 20.03.2019 - Biofrontera AG (NASDAQ: BFRA; Frankfurt Stock Exchange: B8F), an international biopharmaceutical company, today received positive preliminary results for the primary endpoint of its Phase III clinical trial evaluating the safety and efficacy of conventional photodynamic therapy (PDT) with Ameluz(R) and the BF-RhodoLED(R) lamp for the treatment of actinic keratoses (AK) on the extremities as well as the trunk and neck. The study met its primary regulatory endpoint, demonstrating that Ameluz(R) was superior (p<0.0001) to placebo based on its mean total lesion clearance rate of 86% compared to 33% for placebo. These results will be utilized for the filing of the label extension with the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA), which Biofrontera plans to submit in the third quarter of 2019.



The multi-center, randomized, double-blind, intra-individual study included 50 patients at six study sites in Germany, each with four to ten clinically confirmed AK lesions in comparable areas on the right and left side of the extremities and/or trunk/neck. Mild, moderate and severe actinic keratoses were treated with one or two PDT treatments. The final examination of the patients took place three months after the last PDT treatment. The clinical study phase is now followed by a follow-up phase of twelve months after the last PDT, in which recurrence rates and/or numbers of new AKs and skin tumors are determined.



Biofrontera AG, Hemmelrather Weg 201, 51377 Leverkusen

ISIN: DE0006046113

WKN: 604611



Contact: Biofrontera AG

Tel.: +49 (0214) 87 63 2 0, Fax.: +49 (0214) 87 63 290

E-mail: ir@biofrontera.com











20-March-2019 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de

























Language: English
Company: Biofrontera AG

Hemmelrather Weg 201

51377 Leverkusen

Germany
Phone: +49 (0)214 87632 0
Fax: +49 (0)214 87632 90
E-mail: ir@biofrontera.com
Internet: www.biofrontera.com
ISIN: DE0006046113, NASDAQ: BFRA
WKN: 604611
Listed: Regulated Market in Dusseldorf, Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Hamburg, Munich, Stuttgart, Tradegate Exchange; Nasdaq





 
End of Announcement DGAP News Service




789871  20-March-2019 CET/CEST







fncls.ssp?fn=show_t_gif&application_id=789871&application_name=news&site_id=geo_holding_tug
Tilos a hír bármilyen adatbázisba történő mentése vagy annak továbbítása harmadik fél számára;kereskedelmi viszonylatban vagy kereskedelmi céllal csak a Deutsche Gesellschaft für Ad-hoc-Publizität mbh írásos engedélyével történhet.